Table 1.

Summary of measurements for the combination treatment preclinical trial

Groupa	Measurements±SD	P Valuesb
		C (n=22)	T (n=21)	P (n=18)	B (n=20)
%KW/body wt
C	1.87±0.23	–	0.01017b	0.00023b	5.51E-10b
T	1.69±0.20	0.01017b	–	0.58514	0.00019b
P	1.61±0.14	0.00023b	0.58514	–	0.01832b
B	1.43±0.16	5.51E-10b	0.00019b	0.01832b	–
%LW/ERbody wt
C	5.54±0.40	–	0.86211	1.23E-06b	4.91E-07b
T	5.60±0.34	0.86211	–	7.48E-08b	2.75E-08b
P	4.96±0.43	1.23E-06b	7.48E-08b	–	0.99986
B	4.94±0.29	4.91E-07b	2.75E-08b	0.99986	–
Cystic volume (μl)
C	91.31±36.73	–	0.14538	0.00018b	5.16E-08b
T	71.85±34.19	0.14538	–	0.09899	0.00027b
P	50.37±20.58	0.00018b	0.09899	–	0.25587
B	32.48±16.17	5.16E-08b	0.00027b	0.25587	–
Fibrotic volume (μl)
C	5.18±1.98	–	0.02634b	4.33E-07b	7.26E-08b
T	3.72±1.85	0.02634b	–	0.01107b	0.00381b
P	2.10±1.31	4.33E-07b	0.01107b	–	0.99367
B	1.90±1.35	7.26E-08b	0.00381b	0.99367	–
cAMP (pmol/μg protein)
C	4.45±1.53	–	0.68829	0.54057	0.01671b
T	4.06±1.32	0.68829	–	0.99251	0.21733
P	3.92±1.37	0.54057	0.99251	–	0.38158
B	3.28±0.59	0.01671b	0.21733	0.38158	–
Body wt (g)
C	26.32±3.17	–	0.92433	6.71E-06b	4.32E-10b
T	25.72±3.90	0.92433	–	0.00018b	4.79E-10b
P	23.39±2.27	6.71E-06b	0.00018b	–	0.01202b
B	21.37±2.23	4.32E-10b	4.79E-10b	0.01202b	–

C, control (Pkd1^RC/RC, untreated); T, tolvaptan; P, pasireotide; B, both (tolvaptan plus pasireotide).

^aSix-month-old inbred animals.

^bSignificant at P<0.05.